Agencies, 02 September: Covid kelaaf India laga first intranasal dawai te phase 2 trials toh Prakhar hospital, Kanpur te suru korise. Etu dawai toh Bharat Biotech para Washington University School of Medicine in St Louis logote melikena bonaishe. Kanpur toh state tee kala centre ase COVID kelaaf intranasal vaccine trials lowa te. 30 volunteers te doctors, tai khan laga family members aro tusara khan melikena intranasal vaccine laga first dose loise.
Tusara 20 manu khan ahibole olob din te etu dawai lowa thakibo. Dawai laga second dose toh volunteers ke 28 din bechite debole ase. Nasal dawai lowa sob volunteers toh dangor khan (adults) ase koise.
Principal investigator for intranasal Covid vaccine, Dr JS Kushwaha para etu phase of trials te healthy volunteers ke dawai laga doses deya te thek para tolerate korise koise aro eku serious adverse events khobor howa nai koise. Sob volunteers toh under observation te ase koise.
Dr Kushwaha para volunteers ke dawai deya ase. Tai para intranasal dawai laga tuita drops toh volunteer laga each nostril te deshe koise. five munutes laga gap bechite arobe tuita drops toh agae deya nesana eki deshe koise. Etu para sob melikena eight vaccine drops toh ekta man uke deshe koise. Etu bechite volunteer ke toh ek khor opor te observed kora thakise koise. Etu deya dawai laga khobor toh 28 din bechite hobo aro eki procedure toh dubara koribo koise.
Tai para second par intranasal vaccine nadiya agae te volunteer laga saliva aro blood samples toh immunogenicity study koribole nemite jama koribo koise.
Tai para intranasal vaccine toh manu laga nostril te deshe aro etu bechite asti respiratory tract te nami koise. Etu vaccine laga dosage toh Covaxin nesana 28 din bechite repeat hobo koise. Etu intranasal dawai bona toh nostril para he virus te neutralise koribole nemite bona ase koise aro etu para respiratory tract te bachai koise.
Add Comment